Qiagen (QGEN) Q4 2025 earnings summary

Executive summary

• Delivered solid Q4 and FY 2025 results, with net sales and adjusted EPS at or above the high end of outlook ranges, exceeding expectations despite macroeconomic and U.S. government shutdown headwinds.

• Growth pillars (Sample technologies, QuantiFERON, QIAstat-Dx, QIAcuity, QIAGEN Digital Insights) achieved $1.49B in sales, up 8% CER, on track for $2B by 2028.

• Strategic acquisitions of Parse Biosciences and Genoox expanded the portfolio into single-cell analysis and AI-driven bioinformatics.

• Over $1.1B returned to shareholders since 2024, including share repurchases and the first annual dividend.

• Mark Stevenson joined the supervisory board; Ross Levine stepped down but remains as scientific advisory board chair.

Financial highlights

• FY 2025 net sales: $2.09B (+5% CER); Q4 net sales: $540M (+1% CER), both at the high end of guidance.

• Adjusted diluted EPS for FY 2025: $2.40 CER (outlook: $2.38 CER); Q4 adjusted EPS: $0.62 CER.

• Adjusted operating income margin expanded to 29.5% in 2025, up 80 bps despite tariff and currency headwinds.

• Free cash flow for 2025: $453M, supporting investments and shareholder returns.

• Operating cash flow for 2025: $654M, absorbing efficiency initiative payments and higher CAPEX.

Outlook and guidance

• 2026 outlook: at least 5% CER sales growth and adjusted EPS of at least $2.50 CER.

• Q1 2026: net sales growth of at least 1% CER, adjusted EPS of at least $0.54 CER.

• Growth pillars targeted to grow ~9% CER in 2026; Sample technologies $720M, QuantiFERON $535M, QIAstat $160M, QIAcuity $100M, QDI $125M.

• 2028 ambitions reaffirmed: ~7% sales CAGR, at least 31% adjusted operating margin, $2B+ from growth pillars.

• Currency expected to have a positive impact on 2026 net sales and neutral impact on adjusted EPS.